Molecular pathways of angiogenesis inhibition.
A large body of evidence now demonstrates that angiostatic therapy represents a promising way to fight cancer. This research recently resulted in the approval of the first angiostatic agent for clinical treatment of cancer. Progress has been achieved in decrypting the cellular signaling in endothelial cells induced by angiostatic agents. These agents predominantly interfere with the molecular pathways involved in migration, proliferation and endothelial cell survival. In the current review, these pathways are discussed. A thorough understanding of the mechanism of action of angiostatic agents is required to develop efficient anti-tumor therapies.
Tabruyn
Sebastien P
SP
Angiogenesis Laboratory, Department of Pathology, Research Institute for Growth and Development (GROW), University of Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.
Griffioen
Arjan W
AW
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D043168:Angiostatins / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001324:Autoantigens / Q000627:therapeutic use; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D024141:Collagen Type IV / Q000627:therapeutic use; D043169:Endostatins / Q000627:therapeutic use; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010978:Platelet Factor 4 / Q000627:therapeutic use; D019700:Thrombospondin 1 / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D001324:Autoantigens; D024141:Collagen Type IV; D043169:Endostatins; D061965:Matrix Metalloproteinase Inhibitors; D019700:Thrombospondin 1; C057112:type IV collagen alpha3 chain; D010978:Platelet Factor 4; D043168:Angiostatins